AtriCure, Inc. (ATRC) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $29.40. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ATRC = $1,011.04 (+3338.9% from the current price, the stock appears undervalued). Analyst consensus target is ATRC = $51 (+72.3% upside).
Valuation: ATRC trades at a trailing Price-to-Earnings (P/E) of -115.6 (S&P 500 average ~25).
Financials: revenue is $535M, +17.4%/yr average growth. Net income is $11M (loss), growing at +20.7%/yr. Net profit margin is -2.1% (negative). Gross margin is 74.4% (+0 pp trend).
Balance sheet: total debt is $88M against $492M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 3.96 (strong liquidity). Debt-to-assets is 13.5%. Total assets: $654M.
Analyst outlook: 18 / 19 analysts rate ATRC as buy (95%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 66/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
